Evaluation and management of patients with refractory ascites

World Journal of Gastroenterology

Volumn 15, Issue 1, 2009, Pages 67-80

  Senousy, Bahaa Eldeen ^a   Draganov, Peter V ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Albumin infusion; Aquaretics; Large volume paracentesis; Refractory ascites; Transjugular intrahepatic portosystemic stentshunt

Indexed keywords

ALBUMIN; AQUARETIC DERIVATIVE; CLONIDINE; CONIVAPTAN; DEXTRAN 70; DIURETIC AGENT; FUROSEMIDE; LIXIVAPTAN; MANNITOL; MIDODRINE; NORADRENALIN; OCTREOTIDE; PLACEBO; POLYGELINE; POTASSIUM; SATAVAPTAN; SODIUM; SPIRONOLACTONE; TERLIPRESSIN; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; VASOPRESSIN RECEPTOR ANTAGONIST;

ALBUMIN DIALYSIS; ARTIFICIAL EMBOLISM; ASCITES; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG TREATMENT FAILURE; EXTRACORPOREAL CIRCULATION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; INTERMETHOD COMPARISON; ISCHEMIA; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MONOTHERAPY; PARACENTESIS; PATHOGENESIS; PATIENT EDUCATION; PATIENT REFERRAL; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; POTASSIUM URINE LEVEL; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SODIUM RESTRICTION; SODIUM URINE LEVEL; SOLID TUMOR; SURGICAL MORTALITY; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 59249101290     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.67     Document Type: Review

References (171)

1. Reynolds TB. Ascites. Clin Liver Dis 2000; 4: 151-168, vii
2. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, Porayko M, Moreau R, Garcia-Tsao G, Jimenez W, Planas R, Arroyo V. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-266
3. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, Caballeria J, Rodes J, Rozman C. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122-128
4. Cardenas A, Gines P. Management of refractory ascites. Clin Gastroenterol Hepatol 2005; 3: 1187-1191
5. Wongcharatrawee S, Garcia-Tsao G. Clinical management of ascites and its complications. Clin Liver Dis 2001; 5: 833-850
6. Wensing G, Lotterer E, Link I, Hahn EG, Fleig WE. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function. Hepatology 1997; 26: 1149-1155
7. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654
8. Bernardi M, Laffi G, Salvagnini M, Azzena G, Bonato S, Marra F, Trevisani F, Gasbarrini G, Naccarato R, Gentilini P. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993; 13: 156-162
9. Arroyo V, Rodes J. A rational approach to the treatment of ascites. Postgrad Med J 1975; 51: 558-562
10. Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI, Allen MJ, Baum RA, Gadacz TR, Camara DS. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. N Engl J Med 1989; 321: 1632-1638
11. Guevara M, Cardenas A, Uriz J, Gines P. Prognosis of Patients with Cirrhosis and Ascites. In: Gines P, Arroyo V, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. Malden, Mass: Blackwell Science, 2005: 260-271
12. Planas R, Montoliu S, Balleste B, Rivera M, Miquel M, Masnou H, Galeras JA, Gimenez MD, Santos J, Cirera I, Morillas RM, Coll S, Sola R. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4: 1385-1394
13. Wong F, Blendis L. The pathophysiologic basis for the treatment of cirrhotic ascites. Clin Liver Dis 2001; 5: 819-832
14. Arroyo V, Bosch J, Gaya-Beltran J, Kravetz D, Estrada L, Rivera F, Rodes J. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94: 198-201
15. Gines P, Cardenas A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis 2008; 28: 43-58
16. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen K Scholmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176
17. Runyon BA. Refractory ascites. Semin Liver Dis 1993; 13: 343-351
18. Wong F, Massie D, Hsu P, Dudley F. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology 1993; 104: 869-876
19. Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992; 103: 1302-1306
20. Han SH, Reynolds TB, Fong TL. Nephrogenic ascites. Analysis of 16 cases and review of the literature. Medicine (Baltimore) 1998; 77: 233-245
21. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992; 117: 215-220
22. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39: 841-856
23. Pirlich M, Selberg O, Boker K, Schwarze M, Muller MJ. The creatinine approach to estimate skeletal muscle mass in patients with cirrhosis. Hepatology 1996; 24: 1422-1427
24. Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, Alberino F, Gatta A. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994; 154: 201-205
25. Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82: 945-952
26. Spahr L, Villeneuve JP, Tran HK, Pomier-Layrargues G. Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites. Hepatology 2001; 33: 28-31
27. Cho HS, Park GT, Kim YH, Shim SG, Kim J8, Lee OY, Choi HS, Hahm JS, Lee MH. [The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis] Taehan Kan Hakhoe Chi 2003; 9: 324-331
28. Cardenas A, Bataller R, Arroyo V. Mechanisms of ascites formation. Clin Liver Dis 2000; 4: 447-465
29. Gines P, Fernandez-Esparrach G, Arroyo V, Rodes J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17: 175-189
30. Morali GA, Sniderman KW, Deitel KM, Tobe S, Witt-Sullivan H, Simon M, Heathcote J, Blendis LM. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992; 16: 249-250
31. Fernandez-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriguez-Eire JL, Garcia-Plaza A, Leal J. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97: 1304-1312
32. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-1157
33. Valiance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-778
34. Kravetz D, Arderiu M, Bosch J, Fuster J, Visa J, Casamitjana R, Rodes J. Hyperglucagonemia and hyperkinetic circulation after portocaval shunt in the rat. Am J Physiol 1987; 252: G257-G261
35. Guarner C, Soriano G, Such J, Teixido M, Ramis I, Bulbena O, Rosello J, Guarner F, Gelpi E, Balanzo J. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992; 102: 303-309
36. Korthuis RJ, Kinden DA, Brimer GE, Slattery KA, Stogsdill P, Granger DN. Intestinal capillary filtration in acute and chronic portal hypertension. Am J Physiol 1988; 254: G339-G345
37. Dudley FJ. Pathophysiology of ascites formation. Gastroenterol Clin North Am 1992; 21: 215-235
38. Arroyo V, Navasa M. Ascites and Spontaneous Bacterial Peritonitis. In: Schiff ER, Sorrel MF, Maddrey WS. Schiff's diseases of the liver. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2007
39. Rafael Valdivia L, Ferrandiz Quiroz J. [Hyponatremia as a possible mortality factor in cirrhotic patients hospitalised in the Guillermo Almenara Irigoyen State Hospital, 2003-2005] Rev Gastroenterol Peru 2007; 27: 37-46
40. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41: 32-39
41. Bataller R, Gines P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis 1997; 17: 233-247
42. Garcia-Tsao G. Transjugular Intrahepatic Portosystemic Shunt (TIPS) for the Management of Refractory Ascites in Cirrhosis, In: Gines P, Arroyo V, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease:,pathogenesis, diagnosis, and treatment. Malden, Mass: Blackwell Science, 2005: 251-260
43. Cardenas A, Gines P. A Practical Approach to Treatment of Patients with Cirrhosis and Ascites. In: Gines P, Arroyo V, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. Malden, Mass: Blackwell Science, 2005: 286-293
44. Gines P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, Rimola A, Viver J, Camps J, Jimenez W. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234-241.
45. Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, Torres M, Humbert P, Rimola A, Llach J. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502
46. Salerno F, Badalamenti S, Incerti P, Tempini S, Restelli B, Bruno S, Bellati G, Roffi L. Repeated paracentesis and i.v. albumin infusion to treat tense ascites in cirrhotic patients. A safe alternative therapy. J Hepatol 1987; 5: 102-108
47. Kravetz D, Romero G, Argornz J, Guevara M, Suarez A, Abecasis R, Bildozola M,, Valero J, Terg R. Total volume paracentesis decreases variceal pressure, size, and variceal wall tension in cirrhotic patients. Hepatology 1997; 25: 59-62
48. Nevens F, Bustami R, Scheys I, Lesaffre E, Fevery J. Variceal pressure is a factor predicting the risk of a first variceal bleeding: a prospective cohort study in cirrhotic patients. Hepatology 1998; 27: 15-19
49. Fernandez-Esparrach G, Guevara M, Sort P, Pardo A, Jimenez W, Gines P, Planas R, Lebrec D, Geuvel A, Elewaut A, Adler M, Arroyo V. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 1997; 26: 614-620
50. Morillas RM, Santos J, Montoliu S, Planas R. Paracentesis for Cirrhotic Ascites. In: Gines P, Arroyo V, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. Malden, Mass: Blackwell Science, 2005: 241-250
51. Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330: 337-342
52. Soulsby CT, Morgan MY. Dietary management of hepatic encephalopathy in cirrhotic patients: survey of current practice in United Kingdom. BMJ 1999; 318: 1391
53. Gines P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, Liard JF, Martin PY, Schrier RW. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28: 851-864
54. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006; 55 Suppl 6: vi1-vi12
55. Grabau CM, Crago SF, Hoff LK, Simon JA, Melton CA, Ott BJ, Kamath PS. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40: 484-488
56. McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31: 164-171
57. Runyon BA. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986; 146: 2259-2261
58. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27: 264-272
59. Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther 2005; 21: 525-529
60. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96: 1581-1586
61. Runyon BA, Antillon MR, Montano AA. Effect of diuresis versus therapeutic paracentesis on ascitic fluid opsonic activity and serum complement. Gastroenterology 1989; 97: 158-162
62. Pozzi M, Redaelli E, Ratti L, Poli G, Guidi C, Milanese M, Calchera I, Mancia G. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol Dietol 2005; 51: 179-186
63. Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-586
64. Appenrodt B, Wolf A, Grunhage F, Trebicka J, Schepke M, Rabe C, Lammert F, Sauerbruch T, Heller J. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int 2008; 28: 1019-1025
65. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, Angeli P, Ruiz-Del-Arbol L, Planas R, Sola R, Gines P, Terg R, Inglada L, Vaque P, Salerno F, Vargas V, Clemente G, Quer JC, Jimenez W, Arroyo V, Rodes J. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-1010
66. Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, Dadamessi I, Silvain C, Bonny C, Oberti F, Gournay J, Lebrec D, Grouin JM, Guemas E, Golly D, Padrazzi B, Tellier Z. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006; 26: 46-54
67. Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman L, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal & Liver Disease: pathophysiology, diagnosis, management. 8th ed. Philadephia: Saunders, 2006: 1935-1964
68. Wilkinson P, Sherlock S. The effect of repeated albumin infusions in patients with cirrhosis. Lancet 1962; 2: 1125-1129
69. Rothschild MA, Oratz M, Evans C, Schreiber SS. Alterations in Albumin Metabolism after Serum and Albumin Infusions. J Clin Invest 1964; 43: 1874-1880
70. Salo J, Gines A, Gines P, Piera C, Jimenez W, Guevara M, Fernandez-Esparrach G, Sort P, Bataller R, Arroyo V, Rodes J. Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. J Hepatol 1997; 27: 645-653
71. Planas R, Gines P, Arroyo V, Llach J, Panes J, Vargas V, Salmeron JM, Gines A, Toledo C, Rimola A. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 1990; 99: 1736-1744
72. Coll S, Vila MC, Molina L, Gimenez MD, Guarner C, Sola R. Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol 2004; 16: 347-353
73. Cabrera J, Inglada L, Quintero E, Jimenez W, Losada A, Mayor J, Guerra C. Large-volume paracentesis and intravenous saline: effects on the renin-angiotensin system. Hepatology 1991; 14: 1025-1028
74. Sola-Vera J, Such J. Understanding the mechanisms of paracentesis-induced crculatory dysfunction. Eur J Gastroenterol Hepatol 2004; 16: 295-298
75. Christidis C, Mal F, Ramos J, Senejoux A, Callard P, Navarro R, Trinchet JC, Larrey D, Beaugrand M, Guettier C. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001; 35: 726-732
76. Cadranel JF, Gargot D, Grippon P, Lunel F, Bernard B, Valla D, Opolon P. Spontaneous dialytic ultrafiltration with intraperitoneal reinfusion of the concentrate versus large paracentesis in cirrhotic patients with intractable ascites: a randomized study. Int J Artif Organs 1992; 15: 432-435
77. Bernardi M, Rimondi A, Gasbarrini A, Trevisani F, Caraceni P, Legnani C, Palareti G, Gasbarrini G. Ascites apheresis, concentration and reinfusion for the treatment of massive or refractory ascites in cirrhosis. J Hepatol 1994; 20: 289-295
78. Albalate M, Lopez Garcia MD, Vazquez A, De Sequera P, Marriott E, Tan D, Ortiz A, Casado S, Carreno V, Caramelo C. Concentrated ascitic fluid reinfusion in cirrhotic patients: a simplified method. Am J Kidney Dis 1997; 29: 392-398
79. Lata J, Marecek Z, Fejfar T, Zdenek P, Bruha R, Safka V, Hulek P, Hejda V, Dolina J, Stehlik J, Tozzi I. The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites - a randomized multicentric study. Hepatogastroenterology 2007; 54: 1930-1933
80. Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, Poynard T, Binn M, Grange JD, Valla D, Lebrec D. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50: 90-94
81. Singh Ranger G. Terlipressin and arterial blood volume after paracentesis for tense ascites in cirrhosis. Gut 2002; 51: 755
82. Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol 2006; 21: 303-307
83. Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, Bhalla A, Mahi SK. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008; 103: 1399-1405
84. Singh V, Kumar B, Nain CK, Singh B, Sharma N, Bhalla A, Sharma AK. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006; 260: 62-68
85. Rosch J, Uchida BT, Putnam JS, Buschman RW, Law RD, Hershey AL. Experimental intrahepatic portacaval anastomosis: use of expandable Gianturco stents. Radiology 1987; 162: 481-485
86. Casado M, Bosch J, Garcia-Pagan JC, Bru C, Banares R, Bandi JC, Escorsell A, Rodriguez-Laiz JM, Gilabert R, Feu F, Schorlemer C, Echenagusia A, Rodes J. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114: 1296-1303
87. Reichle FA, Owen OE. Hemodynamic patterns in human hepatic cirrhosis: a prospective randomized study of the hemodynamic sequelae of distal splenorenal (Warren) and mesocaval shunts. Ann Surg 1979; 190: 523-534
88. Rossle M, Siegerstetter V, Huber M, Ochs A. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver 1998; 18: 73-89
89. Jalan R, Lui HF, Redhead DN, Hayes PC. TIPSS 10 years on. Gut 2000; 46: 578-581
90. Forrest EH, Stanley AJ, Redhead DN, McGilchrist AJ, Hayes PC. Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis. Aliment Pharmacol Ther 1996; 10: 801-806
91. Ochs A, Rossle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, Huonker M, Langer M, Blum HE. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332: 1192-1197
92. Wong W, Liu P, Blendis L, Wong F. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites. Am J Med 1999; 106: 315-322
93. Nazarian GK, Ferral H, Bjarnason H, Castaneda-Zuniga WR, Rank JM, Bernadas CA, Hunter DW. Effect of transjugular intrahepatic portosystemic shunt on quality of life. AJR Am J Roentgenol 1996; 167: 963-969
94. Allard JP, Chau J, Sandokji K, Blendis LM, Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol 2001; 96: 2442-2447
95. Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology 2003; 124: 1700-1710
96. Pidlich J, Peck-Radosavljevic M, Kranz A, Wildling R, Winkelbauer FW, Lammer J, Mayer C, Muller C, Stix G, Gangl A, Schmidinger H. Transjugular intrahepatic portosystemic shunt and cardiac arrhythmias. J Clin Gastroenterol 1998; 26: 39-43
97. Freedman AM, Sanyal AJ, Tisnado J, Cole PE, Shiffman ML, Luketic VA, Purdum PP, Darcy MD, Posner MP. Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics 1993; 13: 1185-1210
98. LaBerge JM, Ring EJ, Gordon RL, Lake JR, Doherty MM, Somberg KA, Roberts JP, Ascher NL. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology 1993; 187: 413-420
99. Riggio O, Merlli M, Pedretti G, Servi R, Meddi P, Lionetti R, Rossi P, Bezzi M, Salvatori F, Ugolotti U, Fiaccadori F, Capocaccia L. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci 1996; 41: 578-584
100. Sanyal AJ, Freedman AM, Shiffman ML, Purdum PP 3rd, Luketic VA, Cheatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20: 46-55
101. Rossle M, Piotraschke J. Transjugular intrahepatic portosystemic shunt and hepatic encephalopathy. Dig Dis 1996; 14 Suppl 1: 12-19
102. Somberg KA, Riegler JL, LaBerge JM, Doherty-Simor MM, Bachetti P, Roberts JP, Lake JR. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 1995; 90: 549-555
103. Kerlan RK Jr, LaBerge JM, Baker EL, Wack JP, Marx M, Somberg KA, Gordon RL, Ring EJ. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 1995; 6: 917-921
104. Hauenstein KH, Haag K, Ochs A, Langer M, Rossle M. The reducing stent: treatment for transjugular intrahepatic portosystemic shunt-induced refractory hepatic encephalopathy and liver failure. Radiology 1995; 194: 175-179
105. Martinet JP, Fenyves D, Legault L, Roy L, Dufresne MP, Spahr L, Lafortune M, Pomier-Layrargues G. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution. Dig Dis Sci 1997; 42: 161-166
106. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, Lassen C, Benhamou JP, Erlinger S. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996; 25: 135-144
107. La Berge JM, Ferrell LD, Ring EJ, Gordon RL. Histopathologic study of stenotic and occluded transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 1993; 4: 779-786
108. Sanyal AJ, Freedman AM, Luketic VA, Purdum PP 3rd, Shiffman ML, DeMeo J, Cole PE, Tisnado J. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112: 889-898
109. LaBerge JM, Somberg KA, Lake JR, Gordon RL, Kerlan RK Jr, Ascher NL, Roberts JP, Simor MM, Doherty CA, Hahn J. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 1995; 108: 1143-1151
110. Rosado B, Kamath PS. Transjugular intrahepatic portosystemic shunts: an update. Liver Transpl 2003; 9: 207-217
111. Chopra S, Dodd GD 3rd, Chintapalli KN, Rhim H, Encarnacion CE, Palmaz JC, Esola CC, Ghiatas AA. Transjugular intrahepatic portosystemic shunt: accuracy of helical CT angiography in the detection of shunt abnormalities. Radiology 2000; 215: 115-122
112. Angermayr B, Cejna M, Koenig F, Karnel F, Hackl F, Gangl A, Peck-Radosavljevic M. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003; 38: 1043-1050
113. Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, Perreault P, Peron JM, Abraldes JG, Bouchard L, Bilbao JI, Bosch J, Rousseau H, Vinel JP. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126: 469-475
114. Siegerstetter V, Huber M, Ochs A, Blum HE, Rossle M. Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidine with heparin treatment. Hepatology 1999; 29: 33-38
115. Sanyal AJ, Freedman AM, Purdum PP, Shiffman ML, Luketic VA. The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology 1996; 23: 32-39
116. Conn HO. Hemolysis after transjugular intrahepatic portosystemic shunting: the naked stent syndrome. Hepatology 1996; 23: 177-181
117. Sanyal AJ, Reddy KR. Vegetative infection of transjugular intrahepatic portosystemic shunts. Gastroenterology 1998; 115: 110-115
118. Wang MQ, Dake MD, Cui ZP, Wang ZQ, Gao YA. Portal-systemic myelopathy after transjugular intrahepatic portosystemic shunt creation: report of four cases. J Vasc Interv Radiol 2001; 12: 879-881
119. Conn HO, Rossle M, Levy L, Glocker FX. Portosystemic myelopathy: spastic paraparesis after portosystemic shunting. Scand J Gastroenterol 2006; 41: 619-625
120. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rossle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999; 44: 743-748
121. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701-1707
122. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, Nicolini A, Salvatori F. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 629-635
123. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodes J. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-1847
124. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124: 634-641
125. Albillos A, Banares R, Gonzalez M, Catalina MV, Molinero LM. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005; 43: 990-996
126. Deltenre P, Mathurin P, Dharancy S, Moreau R, Bulois P, Henrion J, Pruvot FR, Ernst O, Paris JC, Lebrec D. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int 2005; 25: 349-356
127. Salerno F, Camma C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825-834
128. Park JS, Won JY, Park SI, Park SJ, Lee DY. Percutaneous peritoneovenous shunt creation for the treatment of benign and malignant refractory ascites. J Vasc Interv Radiol 2001; 12: 1445-1448
129. Lasheen AE, Elzeftawy A, Ibrahim S, Attia M, Emam M. Implantation of a skin graft tube to create a saphenoperitoneal shunt for refractory ascites. Surg Today 2007; 37: 622-625
130. Deen KI, de Silva AP, Jayakody M, de Silva HJ. Saphenoperitoneal anastomosis for resistant ascites in patients with cirrhosis. Am J Surg 2001; 181: 145-148
131. Vadeyar HJ, Doran JD, Charnley R, Ryder SD. Saphenoperitoneal shunts for patients with intractable ascites associated with chronic liver disease. Br J Surg 1999; 86: 882-885
132. Zervos EE, Rosemurgy AS. Management of medically refractory ascites. Am J Surg 2001; 181: 256-264
133. Rozenblit GN, Del Guercio LR, Rundback JH, Poplausky MR, Lebovics E. Peritoneal-urinary drainage for treatment of refractory ascites: a pilot study. J Vasc Interv Radiol 1998; 9: 998-1005
134. Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007; 67: 847-858
135. Pham PC, Pham PM, Pham PT. Vasopressin excess and hyponatremia. Am J Kidney Dis 2006; 47: 727-737
136. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69: 2124-2130
137. Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008; 48: 204-213
138. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-1697
139. Krag A, Moller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007; 46: 1863-1871
140. Kalambokis G, Fotopoulos A, Economou M, Tsianos EV. Octreotide in the treatment of refractory ascites of cirrhosis. Scand J Gastroenterol 2006; 41: 118-121
141. Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007; 46: 213-221
142. Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, Pappas C, Katsaraki A, Tsianos EV. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005; 100: 879-885
143. Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, Mason AL, Gutfreund K, Bain VG. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int 2008
144. Lenaerts A, Van Cauter J, Moukaiber H, Meunier JC, Ligny G. [Treatment of refractory ascites with clonidine and spironolactone] Gastroenterol Clin Biol 1997; 21: 524-525
145. Lenaerts A, Codden T, Meunier JC, Henry JP, Ligny G. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology 2006; 44: 844-849
146. Rai RR, Jain P. Combination of clonidine and diuretic in cirrhotic ascites with activated sympathetic nervous system: Would it be a magical bullet? Hepatology 2008; 47: 360
147. Lenaerts A, Codden T, Van Cauter J, Meunier JC, Henry JP, Ligny G. Interest of the association clonidine-spironolactone in cirrhotic patients with ascites and activation of sympathetic nervous system. Acta Gastroenterol Belg 2002; 65: 1-5
148. Henriksen JH, Ring-Larsen H. Hepatorenal disorders: role of the sympathetic nervous system. Semin Liver Dis 1994; 14: 35-43
149. Laffi G, Gentilini P, Romanelli RG, La Villa G. Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. Dig Liver Dis 2003; 35: 660-663
150. Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, La Villa G, Laffi G. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999; 30: 639-645
151. Trotter J, Pieramici E, Everson GT. Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS). Dig Dis Sci 2005; 50: 1356-1360
152. Romanelli RG, La Villa G, Barletta G, Vizzutti F, Lanini F, Arena U, Boddi V, Tarquini R, Pantaleo P, Gentilini P, Laffi G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006; 12: 1403-1407
153. Fernandez J, Monteagudo J, Bargallo X, Jimenez W, Bosch J, Arroyo V, Navasa M. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42: 627-634
154. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Gines P, Rodes J. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409
155. Gines P, Guevara M, De Las Heras D, Arroyo V. Review article: albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther 2002; 16 Suppl 5: 24-31
156. Gines P, Torre A, Terra C, Guevara M. Review article: pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther 2004; 20 Suppl 3: 57-62; discussion 63-64
157. Chang CY, Singal AK, Ganeshan SV, Schiano TD, Lookstein R, Emre S. Use of splenic artery embolization to relieve tense ascites following liver transplantation in a patient with paroxysmal nocturnal hemoglobinuria. Liver Transpl 2007; 13: 1532-1537
158. Pamuk ON, Sonsuz A. The effect of mannitol infusion on the response to diuretic therapy in cirrhotic patients with ascites. J Clin Gastroenterol 2002; 35: 403-405
159. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 922-938
160. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648
161. Runyon BA. Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997; 17: 163-173
162. Veldt BJ, Laine F, Guillygomarc'h A, Lauvin L, Boudjema K, Messner M, Brissot P, Deugnier Y, Moirand R. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36: 93-98
163. Malekzadeh R, Mohamadnejad M, Rakhshani N, Nasseri-Moghaddam S, Merat S, Tavangar SM, Sohrabpour AA. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol 2004; 2: 344-347
164. Malekzadeh R, Mohamadnejad M, Nasseri-Moghaddam S, Rakhshani N, Tavangar SM, Sohrabpour AA, Tahaghoghi S. Reversibility of cirrhosis in autoimmune hepatitis. Am J Med 2004; 117: 125-129
165. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127: 981-985
166. Bories P, Garcia Compean D, Michel H, Bourel M, Capron JP, Gauthier A, Lafon J, Levy VG, Pascal JP, Quinton A. The treatment of refractory ascites by the LeVeen shunt. A multi-centre controlled trial (57 patients). J Hepatol 1986; 3: 212-218
167. Henderson JM, Mackay GJ, Hooks M, Chezmar JL, Galloway JR, Dodson TF, Kutner MH. High cardiac output of advanced liver disease persists after orthotopic liver transplantation. Hepatology 1992; 15: 258-262
168. Hadengue A, Lebrec D, Moreau R, Sogni P, Durand F, Gaudin C, Bernuau J, Belghiti J, Gayet B, Erlinger S. Persistence of systemic and splanchnic hyperkinetic circulation in liver transplant patients. Hepatology 1993; 17: 175-178
169. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11: 336-343
170. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-1660
171. Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, Peck-Radosavljevic M, Gridelli B, Bosch J. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007; 13: 1174-1180